Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Ensysce Biosciences PAINWeek 2026 Symposium
Tech medical symposium

Ensysce Biosciences PAINWeek 2026 Symposium

Analysis based on 7 articles · First reported Aug 20, 2026 · Last updated Aug 20, 2026

Sentiment
10
Attention
1
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement is a routine corporate communication from a small-cap biotech, likely to have minimal direct impact on broader markets. For Forte Biosciences, the symposium may generate modest investor interest in its pipeline, but no immediate financial or regulatory milestones are announced.

Biotechnology Pharmaceuticals
Event Summary

Forte Biosciences, a clinical-stage biotechnology company, announced it will host an educational symposium at PAINWeek 2026 titled 'A New Era in Pain Therapeutics.' The symposium will showcase the company's neural reset strategy for its botanical psychedelic candidate CY200, aimed at treating Complex Regional Pain Syndrome (CRPS), and its proprietary chemical 'safety switch' technologies for next-generation opioids. The event will feature key executives including CEO Lynn Kirkpatrick and President Charles Morrison, along with pain medicine experts Dr. Jeffrey Gudin and Professor Richard Li. The symposium is intended for healthcare professionals and aims to highlight innovative approaches to pain management.

Key Actions
70 Forte Biosciences announced symposium
Entities Involved
stock
Forte Biosciences
Hosting the symposium and presenting its CY200 candidate and safety switch technologies, Ensysce aims to raise awareness and potentially advance its clinical development. The event is a promotional opportunity but does not alter its financial position.
Importance 100.0 Sentiment 10.0
per
Lynn Kirkpatrick
As CEO, Lynn Kirkpatrick is a featured speaker and spokesperson, representing the company's leadership in the symposium.
Importance 60.0 Sentiment 10.0
per
Charles Morrison
As President, Charles Morrison is a featured speaker and spokesperson, highlighting the company's mission and pipeline.
Importance 60.0 Sentiment 10.0
oth
PAINWeek
PAINWeek is the host conference, providing a platform for Ensysce to present its research.
Importance 40.0 Sentiment 0.0
per
Jeffrey Gudin
As a faculty member from the University of Miami Pain Center, Jeffrey Gudin lends clinical credibility to the symposium.
Importance 30.0 Sentiment 0.0
per
Richard Li
As Chief Medical Officer of Cy Biopharma and a member of Ensysce's Clinical Advisory Board, Richard Li contributes expertise to the symposium.
Importance 30.0 Sentiment 0.0
priv
Cy Biopharma
Cy Biopharma is mentioned as the employer of Richard Li, but has no direct role in the event.
Importance 20.0 Sentiment 0.0
exch
Nasdaq
Nasdaq is the exchange where Ensysce is listed, but the event has no direct impact on the exchange.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.